Abstracts tagged "Systemic sclerosis"

Abstract Number: 0679 • ACR Convergence 2025
Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
Parisa Mazrooei, Xuting Rebecca Sheng, Xiaoyun Yang, Lyrialle Han, Samira Jamalian, Daniel Repplinger, Jingxuan He, Evelin Logis, Jeongsup Shim, Angela Hendricks, Lena Wang, Andrew Thorley and Sara Glickstein, Genentech/Roche, South San Francisco
Background/Purpose: There are 3 isoforms of Transforming Growth Factor Beta (TGFb), a cytokine frequently upregulated in fibrosis. Chronic targeting of TGFb1 and TGFb2 for fibrotic…
Abstract Number: 0845 • ACR Convergence 2025
Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression
Zhiyun Gong¹, Rezvan Parvizi², Helen Jarnagin¹, Haobin Chen³, Madeline Morrisson⁴, Tammara Wood⁵, Monique Hinchcliff⁶, Dinesh Khanna⁷ and Michael Whitfield⁸, ¹Dartmouth College, Lebanon, NH, ²Dartmouth, lebanon, NH, ³Dartmouth Collge, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁵Dartmouth, Hanover, NH, ⁶Yale School of Medicine, Westport, CT, ⁷University of Michigan, Ann Arbor, MI, ⁸Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic Sclerosis (SSc) is a clinically and molecularly heterogeneous autoimmune disease. We identified five intrinsic molecular subtypes in SSc by applying semi-supervised machine learning…
Abstract Number: 2488 • ACR Convergence 2025
Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Kanako Chujo¹, Taichi Miyagi¹, Hiromi Shimada², Shusaku Nakashima², Yusuke Ushio¹, Koichi Sugihara², Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Rituximab (RTX) was approved in Japan as a new treatment strategy for systemic sclerosis (SSc). Intravenous rituximab (375mg/m2) is administered once a week for…
Abstract Number: 1875 • ACR Convergence 2025
Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Merle Freitag¹, Maren Claus², Philippe Kolb³, Valeria Falcone⁴, Ivana Andreeva¹, Norbert Blank⁵, Hanns-Martin Lorenz⁶, Georg Schett⁷ and Wolfgang Merkt⁸, ¹Uniklinik Heidelberg, Heidelberg, Germany, ²IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ³INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁴University Medical Center, Freiburg, Freiburg, Germany, ⁵University Hospital Heidelberg, Heidelberg, Germany, ⁶Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The role of autoantibodies in systemic autoimmunity, such as connective tissue diseases (CTD), has been recently highlighted by the successful treatment with CD19-targeting CAR-T…
Abstract Number: 1586 • ACR Convergence 2025
Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Stefano Di Donato¹, Marie-Elise Truchetet², Marco Minerba³, Oliver Distler⁴, JUAN JOSE ALEGRE SANCHO⁵, Yolanda Braun Moscovici⁶, Christina Bergmann⁷, Petros Sfikakis⁸, Jeska de Vries-Bouwstra⁹, Murray Baron¹⁰, Silvia Bellando-Randone¹¹, Lorenzo Dagna¹², Christopher Denton¹³, Madelon Vonk¹⁴, Vanessa Smith¹⁵, Ivan Castellvi¹⁶, Gabriela Riemekasten¹⁷, Andra Balanescu¹⁸, Masataka Kuwana¹⁹, Maria De Santis²⁰, Kamal Solanki²¹, Anastas Batalov²², Vahan Mukuchyan²³, Marco Matucci-Cerinic²⁴, Yannick Allanore²⁵, Francesco Del Galdo²⁶ and Michael Hughes²⁷, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Campus Bio-Medico University of Rome, Taranto, Taranto, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁵Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rambam Heath Care Campus, Haifa, Israel, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Self employed, Montréal, Canada, ¹¹University of Florence, Florence, Florence, Italy, ¹²Ospedale San Raffaele, Milano, Italy, ¹³University College London, UK, London, United Kingdom, ¹⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Ghent University Hospital, Gent, Belgium, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁷University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁸UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁰Humanitas University, Pieve Emanuele, Italy, ²¹Waikato Hospital, Hamilton, New Zealand, ²²Medical University of Plovdiv, Plovdiv, Bulgaria, ²³"Erebuni" Medical Center, Yerevan, Armenia, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Université Paris Cité, Paris, France, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease characterized by vasculopathy, fibrosis, and immune dysregulation. While JAK inhibitors (JAKi) have shown promising immunomodulatory…
Abstract Number: 1558 • ACR Convergence 2025
Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study
Thomas Guedens¹, Elvira Lesmana², Adam Edwinson³, Margaret Breen-Lyles¹, Anukul Karn⁴, Madhusudan Grover¹ and Ashima Makol³, ¹Mayo Clinic, Rochester, Rochester, MN, ²Mayo Clinic, Rochester, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Trinity Health Livonia, Farmington Hills, MI
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem auto-immune disease characterized by peripheral vasculopathy and widespread fibrosis of the skin and internal organs. Up to…
Abstract Number: 0974 • ACR Convergence 2025
Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Xuezhi Hong¹, Yanhua Xiao², shihao zhu³, Yi-Nan Li⁴, Linlin Huang³, Martin Regensburger⁵, Franz Marxreiter⁶, Tim Filla⁷, Andrea-Hermina Györfi⁸, James Adjaye⁹, Jürgen Winkler⁶, Florian Groeber-Becker¹⁰, Jörg Distler¹¹ and Alexandru-Emil Matei¹², ¹Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, Düsseldorf, Germany, ²Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ³Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵Department of Stem Cell Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁶Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Institute for Stem Cell Research and Regenerative Medicine, University Hospital Düsseldorf, Moorenstrasse ⁵, D-⁴⁰²²⁵ Duesseldorf, Germany, Dusseldorf, Germany, ¹⁰Department of Ophthalmology, University Hospital Düsseldorf, ⁴⁰²²⁵, Düsseldorf, Germany, Dusseldorf, Germany, ¹¹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: Previous studies showed that monocyte-derived macrophages become pro-fibrotic in systemic sclerosis (SSc) and contribute to fibroblast activation. Macrophages are, however, a heterogeneous population. Macrophages…
Abstract Number: 0706 • ACR Convergence 2025
Major salivary glands Ultrasound features in a group of patients with systemic sclerosis: a multicentric study
Roberto D'Alessandro¹, Francois Zimmermann², sandrine jousse³, AURORE BLEUZEN⁴, Guillaume Coiffier⁵, Jérôme Avouac⁶, Alain Lescoat⁷ and Yannick Allanore⁸, ¹Rheumatology Unit, Cochin Hospital, Paris, France, Paris, France, ²Internal medicine department, University Hospital of Rennes, Rennes, France, Rennes, France, ³LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ⁴Medical Imaging, University Hospital of Tours, Tours, France, Tours, France, ⁵Dinan Hospital, Dinan, France, ⁶Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁷CHU Rennes University Hospital, Rennes, France, ⁸Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France
Background/Purpose: Ultrasound (US) abnormalities of major salivary glands are frequent in systemic sclerosis (SSc) patients. However, US role is not yet fully understood, and the…
Abstract Number: 0678 • ACR Convergence 2025
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Andrea-Hermina Györfi¹, Ayla Nadja Stuetz², Christina Duesing³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Yi-Nan Li⁶, Celine van Saan⁵, Alexandru-Emil Matei⁷, Alexander Hoelscher⁵, Peter-Martin Bruch⁸, Sarah Koziel⁸, Manuel Roehrich⁹, Mareike Cramer¹⁰, Bernhard Homey⁵, Bjoern Buehring¹¹, Alexander Kreuter¹², Aleksandar Radujkovic⁵, Claus Peter Heußel¹³, Hanns-Martin Lorenz¹⁴, Ricardo Grieshaber-Bouyer¹⁵, Georg Schett¹⁶, Jörg Distler¹⁷ and Wolfgang Merkt¹⁸, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Klinik für Rheumatologie, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁸University Hospital Düsseldorf, Dusseldorf, Germany, ⁹Universitätsmedizin Mainz, Mainz, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany, ¹¹Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, ¹²HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ¹³Thoraxklinik, University of Heidelberg, Heidelberg, ¹⁴Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹⁵University Hospital Erlangen, Erlangen, Germany, ¹⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 2664 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
YOSHINOBU KOYAMA¹, KENTA SHIDAHARA², YU NAKAI², YOSHIHARU SATO³ and YOSHINORI NISHIURA², ¹Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan, ²Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ³DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan
Background/Purpose: Interferons (IFNs) play critical roles in systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), where heightened type I IFN signaling is a hallmark. Elevated…
Abstract Number: 2486 • ACR Convergence 2025
In vitro antifibrotic effects of nerandomilast on cell types relevant to intestinal remodeling and fibrosis in systemic sclerosis
Chang Zeng¹, Leslie Amador¹, Daniela Schloesser¹, Chantelle Simone-Roach¹, Kristen Hall¹, LeeAnne Daley¹, Andrew Mikosz¹, Jochen Schmitz¹, David Ebenezer¹, Peter Nickolaus², Kremena Simitchieva³ and Karim El Kasmi¹, ¹Immunology & Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, ²Immunology & Respiratory Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ³Inflammation Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder marked by immune dysregulation, vasculopathy, and progressive fibrosis affecting the skin and multiple internal organs, including…
Abstract Number: 1874 • ACR Convergence 2025
Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis
Wenying Liang¹, James St. Clair¹, Pei-Suen Tsou², John Varga², Jason S. Knight², Dinesh Khanna² and Ramadan Ali³, ¹University of Michigan, Ann arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arobr, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a systemic disease characterized by fibrosis, autoimmunity, and vasculopathy. Neutrophil extracellular traps (NETs) are web‐like chromatin…
Abstract Number: 1584 • ACR Convergence 2025
Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics
Samuel Good¹, Nahal Ghanoongooi¹, Ju Young Lee², Arissa Young³ and Elizabeth Volkmann¹, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ³UCLA, Los Angeles, CA
Background/Purpose: There is growing evidence that trauma, and in particular adverse childhood experiences (ACEs), play a role in the pathogenesis and exacerbation of systemic autoimmune…
Abstract Number: 1556 • ACR Convergence 2025
Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Alicia Hinze¹, Nishanth Katurkuri², Robert Vassallo², Ami Shah³, Ryan Lennon², Brian Bartholmai² and Cynthia Crowson⁴, ¹Mayo Clinic - Rochester, MN, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable--some patients experience progressive loss of lung function while others…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].